Science and Research

Feasiblility and safety of nintedanib in combination with Nivolumab in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology - An AIO phase Ib trail

Determination of a safe dose for nintedanib+nivolumab combination therapy and the generation of exploratory efficacy data in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology.

Study details
Study-ID: NCT04046614, 2017-001723-45
Study-ID: NCT04046614, 2017-001723-45
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL on steering board
DZL Role: DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 25.05.2018
Completion Date: 15.09.2023
Status: Closed
Status: Closed
DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.